New hope for Crohn's patients when standard drug fails
NCT ID NCT07310095
Summary
This study aims to see if the drug guselkumab can help control Crohn's disease in Chinese patients who initially responded to ustekinumab but then lost that benefit. It will involve 78 participants and will measure improvements in symptoms and intestinal healing over 48 weeks. The goal is to provide a new treatment option for patients who have run out of effective therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.